Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 05 2022
24 05 2022
Historique:
received:
07
12
2021
accepted:
20
04
2022
entrez:
24
5
2022
pubmed:
25
5
2022
medline:
27
5
2022
Statut:
epublish
Résumé
Obesity can initiate, promote, and maintain systemic inflammation via metabolic reprogramming of macrophages that encircle adipocytes, termed crown-like structures (CLS). In breast cancer the presence of CLS has been correlated to high body mass index (BMI), larger mammary adipocyte size and postmenopausal status. However, the prognostic significance of CLS in HER2 + breast cancer is still unknown. We investigated the prognostic significance of CLS in a cohort of 69 trastuzumab-naïve and 117 adjuvant trastuzumab-treated patients with primary HER2 + breast cancer. Immunohistochemistry of tumour blocks was performed for CLS and correlated to clinical outcomes. CLS were more commonly found at the adipose-tumour border (B-CLS) (64.8% of patients). The presence of multiple B-CLS was associated with reduced time to metastatic disease (TMD) in trastuzumab treated patients with BMI ≥ 25 kg/m
Identifiants
pubmed: 35610242
doi: 10.1038/s41598-022-11696-6
pii: 10.1038/s41598-022-11696-6
pmc: PMC9130517
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7802Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
J Immunol. 2015 May 1;194(9):4379-86
pubmed: 25795760
Clin Cancer Res. 2016 May 1;22(9):2283-9
pubmed: 26712688
Mol Oncol. 2013 Jun;7(3):379-91
pubmed: 23228483
Trends Immunol. 2010 Jun;31(6):228-35
pubmed: 20434953
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Cancers (Basel). 2021 May 06;13(9):
pubmed: 34066392
Eur J Cancer. 2013 Nov;49(17):3588-97
pubmed: 23953055
Nat Cancer. 2021 Apr;2(4):400-413
pubmed: 34966897
Cancer Invest. 2010 Nov;28(9):963-8
pubmed: 20690807
Circulation. 2008 Feb 12;117(6):806-15
pubmed: 18227385
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
Immunology. 2018 Dec;155(4):407-417
pubmed: 30229891
Breast Cancer Res. 2020 Jun 17;22(1):65
pubmed: 32552729
Breast. 2018 Feb;37:142-147
pubmed: 29161652
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Cell Metab. 2013 Dec 3;18(6):816-30
pubmed: 24315368
Breast Cancer Res Treat. 2018 Jul;170(1):15-25
pubmed: 29468486
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Nat Med. 2020 Jul;26(7):1054-1062
pubmed: 32461698
J Surg Res. 2008 Sep;149(1):9-14
pubmed: 18262553
J Clin Invest. 2007 Jan;117(1):175-84
pubmed: 17200717
Cancer Prev Res (Phila). 2015 May;8(5):349-58
pubmed: 25720743
Br J Cancer. 2020 Sep;123(5):852-859
pubmed: 32555534
J Lipid Res. 2005 Nov;46(11):2347-55
pubmed: 16150820
J Clin Invest. 2006 Nov;116(11):3015-25
pubmed: 17053832
J Cell Physiol. 2020 Nov;235(11):7900-7910
pubmed: 31943171
Breast Cancer Res. 2017 Jan 19;19(1):8
pubmed: 28103902
Cancer Prev Res (Phila). 2017 Apr;10(4):235-243
pubmed: 28270386
Cancer Prev Res (Phila). 2018 Apr;11(4):227-236
pubmed: 29222346
J Immunol. 2015 Dec 1;195(11):5503-16
pubmed: 26512139
Breast Cancer Res. 2020 Oct 27;22(1):115
pubmed: 33109233
Ann Oncol. 2007 Jun;18(6):977-84
pubmed: 17229773
Lancet Oncol. 2013 May;14(6):461-71
pubmed: 23602601
J Clin Oncol. 2005 Jul 1;23(19):4265-74
pubmed: 15911866
Cell Metab. 2014 Oct 7;20(4):614-25
pubmed: 25242226
J Lipid Res. 2013 Sep;54(9):2423-36
pubmed: 23836106
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Curr Pharmacogenomics Person Med. 2013 Mar 1;11(1):31-41
pubmed: 24179558
Trends Immunol. 2007 Sep;28(9):393-9
pubmed: 17681884
Breast Cancer Res Treat. 2016 Jul;158(1):113-126
pubmed: 27283835
Nat Rev Drug Discov. 2002 Oct;1(10):797-807
pubmed: 12360257
Prev Chronic Dis. 2006 Jul;3(3):A74
pubmed: 16776875
J Clin Oncol. 2009 Dec 1;27(34):5700-6
pubmed: 19884543
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
J Clin Oncol. 2009 Dec 1;27(34):5838-47
pubmed: 19884552
Sci Rep. 2019 Jul 29;9(1):10961
pubmed: 31358801